Teva Changes Its Tune On Substitutable Generic Advair
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva is aggressively developing a fully substitutable generic version of Advair and other AB-rated respiratory products now that FDA has released draft guidance on bioequivalence requirements for the inhaled respiratory drug.
You may also be interested in...
Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair
Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.
Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair
Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.
Advair Competition: Teva’s AirDuo Approved But Not Therapeutically Equivalent
US FDA approves Teva’s fluticasone/salmeterol fixed-dose combination product under the 505(b)(2) NDA route with an asthma indication but no labeling claim for chronic obstructive pulmonary disease.